This article is more than 5 years old. Information may no longer be current.

Oyster Point raises $93 million in Series B financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Oyster Point Pharma has completed $93 million in Series B financing, the company announced in a press release.

Co-led by Invus Opportunities and Flying L Partners in collaboration with Falcon Vision, as well as existing investors New Enterprise Associates and Versant Ventures and new investor Vida Ventures, the funding will be used to support the company’s dry eye disease product portfolio.

Oyster Point’s lead product candidates, OC-01 and OC-02, both delivered via nasal spray, are designed to stimulate the trigeminal parasympathetic pathway to promote natural tear film production, the release said.

Phase 2b clinical studies have shown patients who received OC-01 or OC-02 experienced significant improvements in dry eye signs and symptoms.

“We are grateful to our investors for their partnership and look forward to initiating a phase 3 clinical development program for dry eye disease,” Oyster Point President and CEO Jeffrey Nau, PhD, MMS, said in the release. “Our novel approach to empower patients with dry eye disease to stimulate their own natural tears has tremendous potential. This financing will bring us a step closer to offering much needed relief to patients in an area that has limited treatment options.”